Start the conversation
In the March 26 Private Briefing report "Double Your Money on This Tiny Firm's Super Bug Drug," we told readers that biotech Trius Therapeutics Inc. (Nasdaq: TSRX) was poised for a 100% pop.
And a 100% pop is just what you got - and then some.
It always feels great when one of our predictions works out this way.
This is premium content for Private Briefing subscribers only.